Notal Vision’s ForeseeHome Reaches Milestone of 3 Million Tests

October 12, 2017: By Joan McKenna
Notal Vision's ForeseeHome monitoring device

Notal Vision’s ForeseeHome monitoring device

Notal Vision announced Oct. 5 that patients have used its ForeseeHome monitoring device 3 million times.

It is the first US FDA-cleared home monitoring system for patients with intermediate dry age-related macular degeneration (AMD) at risk for developing wet AMD.

The self-administered test is designed to detect wet AMD at an earlier stage, allowing doctors to treat patients sooner in disease progression and possibly prevent loss of sight.

The system received US clearance in December 2009 and was used in clinical research before being commercially launched in October 2013. It gained Medicare reimbursement in 2016.

In 2010, the National Eye Institute began using the ForeseeHome in a secondary study to AREDS2 in 1,500 patients. Ninety percent of patients who used the device twice weekly and progressed to wet AMD maintained 20/40 or better vision, compared with 62 percent of patients whose diagnosis was during a routine eye exam or visit triggered by symptoms.

Notal Vision is headquartered in Tel Aviv, Israel, with a US office and distribution center in Virginia.

Need Deeper Analysis? Sign up for Market Scope's monthly newsletter to get in-depth coverage of the ophthalmic market, including quarterly procedure volumes based on survey data and meeting coverage from around the world.

Recent Ophthalmic News

US Health Secretary Alex Azar Takes Aim at Rebates in US Senate Hearing

Beyeonics Surgical Raises $11.5 Million in Initial Funding Round

MeiraGTx Raises $75 Million in Initial Public Offering

GenSight to Pursue Approval for LHON Gene Therapy Candidate, Despite Phase III Setback

Optovue Receives FDA Clearance for AngioAnalytics, First OCT Angiography Metrics

Nexy Robotic Retinal Imaging System Receives FDA Clearance

Ocutrx Receives US Patent for Oculenz AR Glasses for Macular Degeneration

Allergan’s Bimatoprost SR Demonstrates Noninferiority to Timolol in Phase III Glaucoma Study

KKR to acquire Envision Healthcare, Including Amsurg ASC Business

Ophthalmologist Carmen Puliafito, MD, Seeks to Regain Medical License

Avedro Gains J Code for Photrexa Formulations in Preliminary CMS Decision

EyeGate Seeks to Study Ocular Bandage Gel in Punctate Epitheliopathy

Nicox, Ironwood to Collaborate on Novel Ophthalmic Treatments

US FDA Approves MDGH’s Moxidectin for Treatment of River Blindness

Bausch + Lomb Enrolls First Patient in Trial for enVista MX60EF Trifocal IOL

Cincinnati Eye Institute Partners with Private Equity Firm to Pursue National Expansion

Ophthotech Enters Gene Therapy Deals with University of Florida, University of Pennsylvania

Teva’s Launches Generic Version of Restasis in Canada

Clearside’s Phase II Trial for DME Candidate Meets Primary Endpoint

Orasis Raises $13 Million in Series B Financing

Coming soon

2018 Optical Coherence Tomography Report: A Global Market Analysis for 2017 to 2023